Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours

BACKGROUND: Tremelimumab, a fully human cytotoxic T-lymphocyte antigen 4 monoclonal antibody, and PF-3512676, a Toll-like receptor-9 agonist, are targeted immune modulators that elicit durable single-agent antitumour activity in advanced cancer. METHODS: To determine the maximum tolerated dose (MTD)...

Descripción completa

Detalles Bibliográficos
Autores principales: Millward, M, Underhill, C, Lobb, S, McBurnie, J, Meech, S J, Gomez-Navarro, J, Marshall, M A, Huang, B, Mather, C B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3670507/
https://www.ncbi.nlm.nih.gov/pubmed/23652314
http://dx.doi.org/10.1038/bjc.2013.227

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3670507/
https://www.ncbi.nlm.nih.gov/pubmed/23652314
http://dx.doi.org/10.1038/bjc.2013.227

Ejemplares similares